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Background: The relationship between appropriateness score, treatment strategy and quality of life (QOL) among
patients with stable ischemic heart disease (SIHD) is not known. In this prospective cohort study, we evaluated
changes in generic and cardiac-specific quality of life in patients with documented SIHD, comparing patients with
revascularization versus those with medical therapy alone, stratified by their appropriateness scores.
Methods: Consecutive patients with SIHD undergoing elective coronary angiogram from November 1st 2008 to
December 1st 2009 completed the Seattle Angina Questionnaire (SAQ) and EQ-5D at the time of procedure and at
1 year. The appropriateness for coronary revascularization was determined at the time of coronary angiography.
Results: Our final cohort consisted of 425 patients, 69.4% of whom underwent revascularization. In the overall
cohort, 272 (64.0%) had appropriate indications for revascularization, while 57 (13.4%) had inappropriate indications
and 96 (22.6%) had uncertain indications. On average, patients improved in most QOL domains, regardless of
treatment strategy and appropriateness score. In patients with appropriate indications, revascularized patients had
greater improvements in both generic (0.073; 95% CI 0.003-0.144; p-value 0.04) and disease-specific indices, including
angina stability (14.6; 95% CI 0.85-28.3; p-value 0.04), physical limitation (9.3; 95% CI 0.71-17.8; p-value 0.03) and disease
perception (12.7; 95% CI4.3-21.1; p-value 0.003) compared to medically treated patients. However, patients with
uncertain and inappropriate indications also had improvements in physical limitation and disease perception with
revascularization compared to medical therapy.
Conclusions: Patients who had appropriate revascularization derived the greatest improvement in QOL compared
with medical therapy.
Keywords: Quality of life, Angina, AppropriatenessBackground
Landmark randomized controlled trials have consistently
shown no difference in death or myocardial infarction
between patients with stable ischemic heart disease (SIHD)
who are treated with optimal medications alone compared
to those treated with revascularization, with either coronary
artery bypass grafting (CABG) or percutaneous coronary
intervention (PCI) [1-3]. Despite this, there is wide regional* Correspondence: harindra.wijeysundera@sunnybrook.ca
1Schulich Heart Centre, Division of Cardiology, Sunnybrook Health Sciences
Centre, University of Toronto, Toronto, Ontario, Canada
2Institute of Health Policy, Management and Evaluation, University of
Toronto, Toronto, Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Wijeysundera et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.variation in the use of coronary revascularization, suggesting
the possible misuse of these invasive therapies [4,5].
The appropriate use criteria for coronary revascularization
were designed to assist physicians balance the potential
benefits of revascularization against its potential harms
[6,7]. Organized jointly by six international cardiovascular
societies, an expert panel used a modified Delphi process to
categorize clinical scenarios into appropriate, uncertain and
inappropriate indications for coronary revascularization
[6,7]. The rationale for the appropriate use criteria in
identifying candidates for revascularization will be
strengthened if one demonstrates a strong relationship
between improved outcomes and revascularization
decisions based on the appropriateness score. Arguably,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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SIHD is reducing symptomatic angina and improving
quality of life, given the equivalence between optimal
medical therapy and revascularization in reducing hard
clinical outcomes. To the best of our knowledge, there are
no data on the relationship between the appropriateness
of revascularization and its impact on quality of life.
Accordingly, our objective in this prospective cohort
study was to address this gap in knowledge by evaluating
changes in generic and cardiac-specific quality of life
over one year in patients with documented SIHD based on
non-emergent coronary angiography, comparing patients
with revascularization versus those with medical therapy,
stratified by their appropriateness scores.Methods
This study was approved by the Institutional Research
Ethics Boards at Sunnybrook Health Sciences Center at
the University of Toronto. All enrolled patients provided
informed consent to participate in the study.i. Data source
Our study cohort consisted of consecutive patients with
stable chronic coronary artery disease who underwent
coronary angiography at the Schulich Heart Center,
Sunnybrook Health Sciences Centre in Toronto, Ontario,
Canada. Patients were recruited from November 1st 2008
to December 1st 2009. We excluded patients whose
indications for angiography were myocardial infarction,
acute coronary syndrome, or valvular heart disease. We
also excluded patients under the age of 20 years and those
with normal coronary arteries, or only mild coronary
artery disease, defined as stenosis less than 70% in severity
(or less than 50% in the left main artery).
Socio-demographic features, co-morbidities, baseline
medications, coronary anatomy, left ventricular (LV)
function, as well as pre-procedural stress testing were
collected. Patients completed two self-administered
quality of life surveys, the Seattle Angina Questionnaire
(SAQ) and the EQ-5D just prior to the baseline angiogram,
with follow-up at 1 year. The questionnaires were mailed
to patients for completion, with telephone reminders
provided. Abstracted data were linked using unique
patient identifiers to population-based administrative
databases housed at the Institute for Clinical Evaluative
Sciences (ICES). Death was ascertained through linkage
with the Ontario Registered Persons Database (RPDB).
Subsequent cardiac procedures were determined through
linkage with the Canadian Institute for Health Information
Discharge Abstract Database (CIHI-DAD) and Same-Day
Surgery database (CIHI-SDS). These contain data on
all in-hospital and outpatient procedures, as well as acute
hospitalizations.ii. Measures
a. Seattle Angina Questionnaire (SAQ)
The SAQ is a 19-item descriptive, self-administered
questionnaire that focuses on impairments in health unique
to coronary disease, across five dimensions: physical
limitation, anginal stability, anginal frequency, disease
perception and treatment satisfaction [8]. Each dimension
is scored and analyzed separately on a continuous scale
with a range from 0 to 100, with higher scores indicating
better quality of life [8]. A clinically relevant improvement
in the SAQ that reflects a change that is perceptible to
patients is an improvement of 10 points, while a substantial
improvement in clinical status is considered to be an
increase of 20 points [8].
b. EQ-5D
The EQ-5D measures the preference for health status
using a single index score that has two anchors, with a
low score of 0 representing death, and an upper ceiling
of 1, representing perfect health [9]. The EQ-5D covers
five dimensions of health: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression [9].
Each dimension is measured using a three-level ordinal
scale and a unique health state is defined by a combination
of values on each of the five dimensions [9]. Each of the
243 potential health states is assigned a score by applying
a country-specific tariff. US tariffs were used in this study
[9]. To provide clinical context, previous studies have
found that Canadian Cardiovascular Class (CCS) 2 is
associated with an EQ-5D score of 0.77, while CCS 4
is associated with a score of 0.72 [10].
iii. Treatment category
Patients were assigned to the revascularization category
if they underwent a PCI or CABG within 90 days of
index angiogram. All other patients were assigned to the
medical therapy category.
iv. Appropriateness category
The appropriateness for coronary revascularization was
determined based on data collected at the time of the
index angiogram. For this study, we used the 2009
appropriate use criteria, and restricted our analyses to the
59 indications related to SIHD [7]. Briefly, each patient
was assigned an appropriateness score from 1 to 9, based
broadly on coronary anatomy (single versus double versus
triple vessel coronary artery disease), the severity of symp-
toms (based on Canadian Cardiovascular (CCS) class), the
intensity of anti-anginal medications and the extent of
ischemia on non-invasive stress testing [6,7]. For each
patient, the score was calculated automatically using
a computer algorithm. Patients were categorized into
those with appropriate indications for revasculariza-
tion (score of 7–9), uncertain indications (score of
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that could not be assigned appropriateness scores
were excluded from the analyses [6,7].v. Analysis
a. Missing data
In our primary analyses for each quality of life measure,
we included all patients with complete data at baseline
and 1 year for that particular quality of life indicator.
As we anticipated that the same patient may have
varying degrees of missingness for each outcome, this
would result in potentially different sample sizes for
the primary analyses for each outcome. Importantly,
to determine if our conclusions were affected by
missing data, we created five imputed datasets, using
Markov Chain Monte Carlo methods to impute missing
data, which were assumed to be missing at random.
Regression coefficient estimates were then combined
from each imputed dataset to allow for valid statistical
inference.b. Model development
Comparison of baseline characteristics between patients in
each treatment group was evaluated using the Wilcoxon
Rank Sum test for continuous data, and Chi-square or
Fisher exact tests for categorical data.
We created six unadjusted linear regression models,
each with the scores from the EQ-5D or one of the five
domains of the SAQ, treated as a continuous dependent
variable. The unit of analysis for all models was the
individual patient. To account for the repeated measures
per patient, we used generalized estimating equation
(GEE) methods, with each patient having both a baseline
and a 1-year score. Variables included in the model
were time (baseline versus 1 year), treatment strategy
(medical therapy versus revascularization), appropriate-
ness category (appropriate versus inappropriate versus
uncertain) and all 2-way and 3-way interactions between
time, appropriateness category and treatment strategy. In
this manner, we were able to contrast quality of life
changes from baseline to 1 year for patients treated with
revascularization compared to medical therapy alone,
within each appropriateness category. Finally, fully
adjusted models comparing within and between group
changes over time were developed as above, by forcing in
all baseline characteristics into the regression. In these
models, we adjusted for factors that may impact the qual-
ity of life, independent of the choice of revascularization.
These included baseline age, gender, LV function, serum
creatinine, presence of diabetes mellitus, hypertension,
hyperlipidemia, stroke, peripheral vascular disease, smok-
ing, malignancy, heart failure, in addition to having a prior
MI, CABG or PCI.Sensitivity analyses
Given the higher clinical threshold for considering CABG,
as opposed to PCI, as well as the potential for differential
benefit between the two treatments, we repeated all the
adjusted models, stratified by the type of revascularization
modality.
Statistical analyses were performed using SAS version
9.3 (SAS corporation). Results were considered statistically
significant with a 2-sided p-value of <0.05.
Results
During the 1 year of patient accrual, 761 consecutive
patients were enrolled. Of these, 282 patients had either
mild coronary disease or normal coronaries arteries. A
further 54 (7.1%) patients could not be assigned an
appropriateness score because they had missing data
on a previous stress testing. Our final cohort consisted of
425 patients, with 295 (69.4%) patients treated with
revascularization within 90 days of their index angiogram.
Of these, 78 (26.4%) patients underwent CABG, with a
mean delay of 16.7 days (median 10, interquartile range
0–29 days), while 217 (73.6%) underwent PCI, at a mean
delay of 2.5 days (median 0, interquartile range 0–0 days).
Within the final cohort, 272 (64.0%) had appropriate
indications for revascularization, while 57 (13.4%) had
inappropriate indications, and 96 (22.6%) had uncertain
indications respectively. All of the 57 patients who had
inappropriate indications had single or double vessel
disease without involvement of the LAD and 40.4% were
asymptomatic. The majority (51 patients/89.4%) were
patients who were receiving minimal or no anti-anginal
medications, with low-risk findings on non-invasive testing
and were either asymptomatic (n = 17) or minimally
symptomatic with CCS 1–2 (n = 34). The remaining 6
inappropriate patients were all asymptomatic, and had
either low-risk non-invasive findings and were on maximal
anti-anginal medical therapy (n = 4), or intermediate
findings with minimal/no medications (n = 2). In the
appropriate indication category, 75% of the patients
underwent revascularization. In contrast, 53% of the
patients with inappropriate indications underwent revas-
cularization. Of the 96 patients with uncertain indications,
62% underwent revascularization.
The baseline characteristics for the cohort are shown
on Table 1. Only 19.8% of patients were asymptomatic,
with CCS 0 angina. Of the 425 patients in the cohort,
44.2% had single vessel disease, with 31.3% having double
vessel disease and 24.6% having either triple vessel or left
main artery disease. As expected, there were substantial
differences between appropriateness categories in terms of
the distribution of symptoms and anatomy, given that
these are components of the appropriate use criteria.
There were no statistically significant differences in the
distribution of LV function. Only 26.1% of the overall














Age Mean ± SD 65.34 ± 10.86 66.04 ± 11.04 64.11 ± 10.90 64.09 ± 10.23 0.852 65.52 ± 11.69 65.26 ± 10.49 0.823
Male 79.1% 80.1% 78.9% 76.0% 0.123 84.6% 76.6% 0.155
Diabetes 35.1% 38.2% 21.1% 34.4% 0.047 36.9% 34.2% 0.593
Hypertension 74.8% 75.0% 73.7% 75.0% 0.475 80.8% 72.2% 0.152
Hyperlipidemia 89.9% 89.7% 89.5% 90.6% 0.443 90.8% 89.5% 0.764
Smoking 60.0% 62.1% 52.6% 58.3% 0.409 53.1% 3.1% 0.061
Symptom Severity
CCS 0 19.8% 12.1% 40.4% 29..2% <0.001 23.1% 18.3% 0.029
CCS 1-2 48.9% 44.1% 59.6% 56.3% 54.6% 46.4%
CCS 3-4 31.3% 43.8% 0% 14.6% 22.3% 35.3%
LV ejection Fraction
> = 60% 56.0% 54.4% 68.4% 53.1% 0.371 48.5% 59.3% 0.039
40-59% 21.9% 22.4% 14.0% 25.0% 30.0% 18.3%
20-39% 9.4% 11.0% 8.8% 5.2% 10.0% 9.2%
<=20% 0.7% 0.7% 0.0% 1.0% 1.5% 0.3%
NA 12.0% 11.4% 8.8% 15.6% 10.0% 12.9%
Coronary Anatomy
1 -or 2 vessel CAD without involvement of proximal LAD 55.1% 40.8% 100.0% 68.8% <.001 63.8% 51.2% 0.016
Chronic total occlusion of 1 major epicaridial coronary
artery without other coronary stenoses
0.5% 0.7% 0.0% 0.0% 0.568 0.0% 0.7% 0.347
1- vessel CAD involving the proximal LAD 8.0% 8.8% 0.0% 10.4% 0.051 4.6% 9.5% 0.088
2-vessel CAD involving the proximal LAD 4.7% 3.7% 0.0% 10.4% 0.005 4.6% 4.7% 0.953
3-vessel CAD (no left main) 18.8% 25.7% 0.0% 10.4% <.001 17.7% 19.3% 0.692
left main stenosis 13.4% 21.0% 0.0% 0.0% <.001 9.2% 15.3% 0.093
Previous CABG 16.7% 19.9% 1.8% 16.7% 0.005 28.5% 11.5% <.001
Previous CHF 6.4% 6.6% 3.5% 7.3% 0.74 12.3% 3.7% 0.003
Previous PCI 29.9% 29.4% 29.8% 31.3% 0.159 34.6% 27.8% 0.11
Prior MI 34.8% 33.8% 28.1% 41.7% 0.236 43.1% 31.2% 0.043
PVD 12.5% 11.8% 12.3% 14.6% 0.806 13.8% 11.9% 0.553
Creatinine Mean ± SD 95.92 ± 68.21 90.89 ± 23.96 94.46 ± 44.47 111.04 ± 132.88 0.221 106.38 ± 106.79 91.31 ± 40.45 0.971
Dialysis 1.4% 0.7% 1.8% 3.1% 0.227 2.3% 1.0% 0.299




















Table 1 Baseline Characteristics (Continued)
Dementia 0.7% 0.7% 0.0% 1.0% 0.341 0.8% 0.7% 0.102
Cancer 10.4% 11.8% 8.8% 7.3% 0.703 7.7% 11.5% 0.01
COPD 7.5% 8.8% 7.0% 4.2% 0.327 (4.6% 8.8% 0.131
Medications
% on Maximal Anti-anginal Therapy 26.1% 32.0% 7.0% 20.8% <.001 20.8% 28.5% 0.096
ACE inhibitor/ARB 67.5% 66.9% 68.4% 68.8% 0.936 72.3% 65.4% 0.163
Statin 82.1% 83.1% 82.5% 79.2% 0.688 81.5% 82.4% 0.836
Β-Blocker 66.4% 68.8% 56.1% 65.6% 0.184 71.5% 64.1% 0.133
Treatment Strategy
CABG 18.4% 21.7% 14.0% 11.5% 0.002 0.0% 26.4% <.001
Medical 30.6% 24.6% 47.4% 37.5% 130 100.0% 0.0%
PCI 51.1% 53.7% 38.6% 51.0% 0.0% 73.6%
Outcomes
1- year Mortality 2.6% 2.6% 0.0% 4.2% 0.292 5.4% 1.4% 0.016
1-year Readmission for MI 9.9% 10.3% 7.0% 10.4% 0.738 5.4% 11.9% 0.039
1-year repeat PCI/CABG 10.4% 12.5% 3.5% 8.3% 0.098 5.4% 12.5% 0.026
SD: standard deviation; CCS: Canadian Cardiovascular Society; LV: left ventricular; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; MI: myocardial infarction; PVD: peripheral vascular
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statin, β-blockers and ACE inhibitor/ARB medications
were high among the cohort, with no differences between
appropriateness groups (Table 1). Over a 1- year follow-up
period mortality after the index angiogram was 2.6%; 9.9%
of the cohort had a repeat MI within 1 year, while 10.4%
underwent repeat PCI/CABG within 1 year. There were
no differences among the three appropriateness categories
in these outcomes; however, patients who were vascularized
had a lower unadjusted mortality, but higher rates of both
readmission for MI and repeat revascularization.
Quality of life
There was varying degrees of missing data for the six
quality of life measures at the two time points of our
study. As seen in (Additional file 1: Table S1), only 4.7%
(n = 20) of the patients were missing baseline angina
frequency scores, but almost 50% were missing angina
stability at 1 year. Of the 425 patients, only 113 patients
had complete data on all six quality of life measures for
both time points. In (Additional file 1: Table S1), the
sample size for the primary analyses for each quality
indicator is shown. As expected this varied from 252
with complete data on EQ-5D to 213 with complete
data on angina stability. Comparison of the patients
with missing quality of life measures and those with
complete data is found in (Additional file 1: Table S2).
The groups were similar with no differences in baseline
characteristics. In particular, the proportion of patients
that had appropriate, uncertain and inappropriate indica-
tions was similar for the complete dataset and that with
missing data (Additional file 1: Table S2).
Summary results for our primary analysis on patients with
complete data are shown on Figure 1a-f. As is apparent,
most quality of life indices had either statistically significant
improvements or remained constant over the 1 year,
regardless of appropriateness indication or treatment
strategy. Indeed, we did not find a gradient between
the appropriate, uncertain or inappropriate criteria.
The exception was in patients treated medically who
had inappropriate indications for revascularization;
these patients had a significant worsening in their mean
physical limitation scores over the 1 year (Figure 1c).
Angina frequency and angina stability improved signifi-
cantly for all patients, except those who had inappropriate
indications and were treated medically (Figure 1a and 1b
respectively). Disease perception improved significantly
over the course of the 1-year follow-up in all groups
(Figure 1d). Treatment satisfaction only improved signifi-
cantly for patients with appropriate indications who were
revascularized. In (Additional file 1: Table S3), we
compared the proportion of patients who had substantial
improvements (>20 point) over the 1-year of follow-up in
the SAQ sub-scales. Patients who were revascularized hada higher proportion of patients with substantial improve-
ments in angina frequency (33.9% vs 15.4%; p < 0.001),
physical limitation (20% vs 5.4%; p < 0.001) and disease
perception 31.9% vs 20% p = 0.012). However, across
the appropriate use criteria, the only difference was
in physical limitation (18.0% for appropriate vs 5.3%
inappropriate p = 0.052).
A comparison of baseline quality of life measures for the
patients with complete and missing data, stratified by appro-
priateness category is found in (Additional file 1: Table S4).
There were no significant differences in baseline scores for
the five angina specific measures from the SAQ, except for
physical limitation where patients with missing values had
lower scores. There were also differences in generic quality
of life as measured by the EQ-5D. Patients with missing
data tended to have lower baseline quality of life as
measured in the EQ-5D.
Appropriate indications
In the appropriate category, patients who were treated with
revascularization tended to have lower baseline quality of
life scores compared to medical therapy patients
(Figure 1a-f). However, when comparing risk-adjusted
changes over time (Table 2), there were statistically signifi-
cant differences in the angina stability, physical limitation,
disease perception and treatment satisfaction SAQ sub-
categories, as well as in generic EQ-5D in patients with
appropriate indications for revascularization who were
revascularized compared to those who were treated
medically. In each of these categories, patients who
had appropriate indications and were revascularized
had incrementally greater improvements in quality of
life compared to those who were treated medically.
Inappropriate and uncertain indications
Interestingly, patients who had inappropriate indications
for revascularization also had greater improvements in
disease perception and physical limitation when treated
with revascularization compared to medical therapy
(Table 2). Similarly, patients with uncertain indications
had greater improvements in physical limitation with
revascularization.
Sensitivity analyses
Multiple imputation was used to account for missing data.
As seen in the (Additional file 1: Table S5), although there
were no qualitative differences in the trend of our results
when compared to our primary analysis, the findings were
no longer statistically significant.
The risk-adjusted models, stratified by revascularization
modality are found in (Additional file 1: Table S6). We
found similar findings for patients treated with CABG, as
compared to the overall primary results for both patients
with appropriate and inappropriate indications. However,
Figure 1 Changes in quality of life from baseline to 1 year. a-f: Changes in quality of life from baseline to 1 year are shown for patients
categorized by treatment strategy and appropriateness category. P-values are based on per patient changes over time. For angina frequency
(Figure 1a), higher scores represent less frequent angina.
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Table 2 Comparisons of Changes in Quality of Life Indices from baseline to 1 year
Comparison Unadjusted (95% CI) p-value Adjusted (95% CI) p-value
ANGINA FREQUENCY: n = 247
Indication Therapy
Appropriate Revascularization VS medical therapy 10.2 (−0.6,20.9) 0.063 9.8 (−1.6,21.2) 0.093
Inappropriate Revascularization VS medical therapy 13.6 (−2.1,29.3) 0.090 10.0 (−6.2,26.2) 0.227
Uncertain Revascularization VS medical therapy 10.6 (−1.7,22.9) 0.09 11.3 (−1.3,24.0) 0.080
ANGINA STABILITY: n = 213
Indication Therapy
Appropriate Revascularization VS medical therapy 14.6 (0.8,28.3) 0.038 14.6 (0.8,28.3) 0.038
Inappropriate Revascularization VS medical therapy 13.0 (−17.3,43.3) 0.401 9.7 (−20.4,39.7) 0.529
Uncertain Revascularization VS medical therapy −9.4 (−35.1,16.3) 0.475 −7.7 (−34.4,19.0) 0.571
PHYSICAL LIMITATION: n = 239
Indication Therapy
Appropriate Revascularization VS medical therapy 10.1 (1.8,18.5) 0.017 9.3 (0.7,17.8) 0.034
Inappropriate Revascularization VS medical therapy 18.3 (5.8,30.8) 0.004 17.7 (3.9,31.6) 0.012
Uncertain Revascularization VS medical therapy 19.3 (8.6,29.9) <0.001 19.2 (8.2,30.1) <0.001
DISEASE PERCEPTION: n = 243
Indication Therapy
Appropriate Revascularization VS medical therapy 14.4 (5.6,23.1) 0.001 12.7 (4.3,21.1) 0.003
Inappropriate Revascularization VS medical therapy 26.0 (13.6,38.5) <0.001 26.9 (13.6,40.3) <0.001
Uncertain Revascularization VS medical therapy 7.2 (−4.8,19.1) 0.239 6.5 (−5.7,18.8) 0.294
TREATMENT SATISFACTION: n = 246
Indication Therapy
Appropriate Revascularization VS medical therapy 7.6 (2.1,13.1) 0.007 7.6 (1.9,13.2) 0.009
Inappropriate Revascularization VS medical therapy 4.5 (−4.1,13.1) 0.302 6.0 (−2.5,14.5) 0.167
Uncertain Revascularization VS medical therapy 1.2 (−8.4,10.9) 0.802 1.7 (−8.1,11.4) 0.733
EQ_5D: n = 252
Indication Therapy
Appropriate Revascularization VS medical therapy 0.095 (0.024,0.165) 0.008 0.073 (0.003,0.144) 0.040
Inappropriate Revascularization VS medical therapy −0.010 (−0.0168,0.148) 0.902 −0.009 (−0.189,0.171) 0.920
Uncertain Revascularization VS medical therapy 0.062 (−0.012,0.135) 0.099 0.063 (−0.014,0.139) 0.107
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indications, improvements in quality of life were limited
to treatment satisfaction and disease perception.
Discussion
We found that the majority of patients with significant
SIHD who underwent coronary angiography had appropri-
ate indications for revascularization. Approximately
three quarters of these patients underwent subsequent
revascularization. Most patients had improvements in
their self-reported quality of life in the first year after
coronary angiography. Although patients with appropriate
indications for revascularization derived greater improve-
ments with revascularization compared to medical therapy,
improvements were also seen for revascularized patientswith uncertain and inappropriate indications, albeit in fewer
quality of life sub-categories. However, these findings were
not robust in sensitivity analyses that accounted for missing
data with multiple imputations, and were most apparent in
patients who underwent CABG, as opposed to those who
were revascularized with PCI. Although appropriate use
criteria appear to identify appropriate candidates for
revascularization, our study raises doubts as to the
utility of these criteria in excluding patients who are
not candidates for revascularization.
There has been substantial interest in the development
for appropriate use criteria for diagnostic tests and
therapies, particularly in cardiovascular disease [11-13].
These appropriate use criteria are developed through the
expert consensus, and as such it is important to evaluate if
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work from our group has validated the appropriateness
criteria for revascularization by demonstrating that in
SIHD patients who have appropriate indications, medical
therapy was associated with worse outcomes when
compared to revascularization, with a 39% increased
hazard of death or repeat myocardial infarction over 3 years
of follow-up [14]. Moreover, we found that revasculariza-
tion was underutilized, with about 30% of patients with
appropriate indications not receiving revascularization [14].
However, we did not find worse outcomes in revascularized
patients who had uncertain or inappropriate indications, a
finding consistent with other studies [14,15]. We extend
this previous work in the current study by evaluating
the impact of under and overutilization of coronary
revascularization on quality of life.
Quality of life is increasingly used as a patient-centered
endpoint in cardiovascular disease studies, especially in
SIHD, where invasive therapy is indicated for the relief of
symptoms [16,17]. In the landmark Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) trial, both patients treated with optimal
medical therapy and those revascularized with PCI,
had marked improvements in their quality of life as
measured on the SAQ [18]. Patients who were treated
with PCI had small incremental benefits over medical
therapy, which was most prominent in the patient subgroup
with more severe angina symptoms at baseline [18]. This is
consistent with other evidence that has shown that the
most important predictor of quality of life improvements
post PCI is the severity of baseline angina [19]. Our study
adds to these previous findings. Similar to the COURAGE
trial, we found that the majority of patients tended
to have improvements in quality of life. The greater
benefit associated with revascularization compared to
medical therapy seen in our study, in contrast to the
COURAGE trial, maybe related to the relatively low
proportion of patients in our cohort who on maximum
anti-anginal therapy.
In patients with appropriate indications, we have
reinforced the validation of the appropriate category,
given the improved quality of life we observed for patients
treated with revascularization who had appropriate
indications. In combination with our previous work
showing improved clinical outcomes for these patients
with revascularization, this supports the use of the
appropriate use criteria in identifying suitable candidates
for revascularization.
The interpretation of the quality of life changes in
the uncertain and inappropriate categories is complex.
The rationale underlying the inappropriate indication
category is that revascularization in these patients should
not be of any benefit at all, and potentially harmful
because these patients have minimal chest pain and goodbaseline function. However, despite the relatively small
number of patients in these categories, we found that
revascularization in patients with both uncertain and
inappropriate criteria appeared to have greater improve-
ments in quality of life in some of the SAQ sub-categories
when compared to medical therapy. This suggests the
appropriate use criteria may need greater refinement in
order to better exclude patients who are indeed poor
candidates for revascularization. The lack of discrimination
for the appropriateness guidelines for clinical benefit may
relate to the inclusion of symptomatic patients in the
inappropriate category. Indeed, of the 57 patients with
inappropriate indications, 60% had symptoms. Potential
refinements may be the inclusion of quality of life as mea-
sured on instruments such as the SAQ, as opposed to CCS
class, in order to better identify patients with minimal
symptoms who would not benefit from revascularization.
Our study must be interpreted in the context of several
limitations that merit discussion. First, despite our best
efforts, a considerable portion of enrolled patients did not
complete all the quality of life surveys. We evaluated the
impact of missing data in the sensitivity analyses through
multiple imputations. Although it is reassuring that the
qualitative direction of our results were maintained,
the comparisons between treatment strategies within
appropriateness categories were not longer statistically
significant. Second, our analysis was restricted to patients
who survived at least a year after their index coronary
angiogram. This limitation is mitigated by the fact that we
were evaluating a SIHD population and therefore, we
would not expect a high mortality rate. In addition, it is
notable that only approximately a quarter of our patients
were on optimal medical therapy, reflecting the inadequacy
of routine medical care in real world practice. Our
cohort consisted of patients recruited at a single,
large tertiary academic hospital in Ontario, Canada.
Indeed, previous work from our group suggests that
there maybe a higher threshold for invasive testing in
Canada, and as such our results may not be generalizable
to other jurisdictions or patient populations [4]. We were
limited in the anatomical data available to the location of
the lesions. Although this was sufficient to assign patients
to appropriateness categories, we were not able to account
for the complexity of anatomy, such as the presence
of calcification or bifurcation status which may have
impacted the decision to revascularize. Finally, this is
an observational study designed to evaluate associations
between treatment strategy, appropriate use criteria and
outcomes. We cannot establish causality, and so our work
should be considered hypothesis generating and not
conclusive. We believe that our results reinforce the
need for an adequately powered randomized trial to
evaluate the benefit of determining treatment strategy
based on appropriate use criteria.
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In conclusion, we found that coronary revascularization is
associated with greater improvements in quality of life
compared to medical therapy, in particular in patients with
appropriate indications. However, refinements are needed
in the appropriate use criteria to better exclude patients
who would not derive benefit from revascularization.
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